Miranda Dini has announced the launch of GOLD Strategy & Communications, a global healthcare consultancy designed to provide ...

GRI Bio has announced positive topline results from its phase 2a clinical trial evaluating GRI-0621 in idiopathic pulmonary ...

Johnson & Johnson has reported groundbreaking results from the phase 3 MajesTEC-3 study, highlighting the potential of ...

Genfit has announced encouraging preliminary results from its phase 1b clinical trial evaluating investigational drug GNS561 in combination with a MEK inhibitor (MEKi) in patients with KRAS mutated ...

Enterprise Therapeutics has announced the publication of results from its phase 1 study of ETD001, a long-acting inhaled ...

Steven Pipe, Professor of Pediatrics and Pathology at the University of Michigan, explained: “The five-year HOPE-B results ...

Modus Therapeutics Holding AB has announced that the first patient has been dosed in part 2 of its ongoing phase 2a clinical study evaluating sevuparin for the treatment of chronic kidney disease (CKD ...

Johnson & Johnson has welcomed the decision by the Scottish Medicines Consortium (SMC) to accept Rybrevant (amivantamab) in combination with carboplatin and pemetrexed for use within NHS Scotland as a ...

Johnson & Johnson has announced updated results from the phase 3 CARTITUDE-4 study, showing that CARVYKTI (ciltacabtagene autoleucel; cilta-cel) can deliver durable treatment-free remissions as early ...